Опубликовать статью

Информационное партнерство

Инфоресурсы

Контакты

«

Vol. 16, Art. 72 (pp. 779-790)    |    2015       

»

Influence of pathogen reduction on quality and parameters of biological value parameters of donor’s blood components

Chechetkin A.V., Kasjanov A.D., Soldatenkov V.E., Makeev A.B.

Federal state budgetary establishment «Russian science research institute of hematology and transfusiology Federal medico-biologic agency»

Brief summary

In article materials about influence of methods of pathogen reduction on quality and biological properties of components of blood are resulted. It is shown, that processing of fresh frozen plasma and platelets by the methods based on photochemical reactions and a light irradiation, is accompanied by changes of haemostatic potential and a degree of clinical efficiency which expressiveness depends on features of action pathogen reduction technologies. Changes of biological value of pathogen reduction components of blood is expedient for taking into account at realization transfusion therapies at patients of a various diseases.


Key words

pathogen reduction, blood components, fresh frozen plasma, platelet concentrate, clinical efficiency.

Reference list

1. Yokoyama T. Removal of small non-enveloped viruses by nanofiltration / T. Yokoyama , A.Wakisaka , M. Tanifuji et al. // Vox. Sang. – 2004. – Vol. 86, № 4. – R. 225- 229.


2. Heger A. A biochemical comparison of a pharmaceutically licensed coagulation active plasma (Octaplas) with a universally applicable development product (Uniplas) and single-donor FFPs subjected to methylene-blue dye and white-light treatment / A. Heger , J. Römisch , T.E. Svae // Transfus. Apher. Sci. – 2006. – Vol. 35, № 3. – R. 223- 233.


3. Mohr H. Inactivation of pathogens in single units of therapeutic fresh plasma by irradiation with ultraviolet light / H. Mohr , U. Gravemann , T.H. Müller. // Transfusion. – 2009. – Vol. 49, № 10. – R. 2144-2151.


4. Chechetkin A.V. Predyprejdenie inficirovaniya VICh pri perelivanii donorskoi krovi i ee komponentov / A.V. Chechetkin, A.B. Makeev, V.E. Soldatenkov, i dr. // VICh-infekciya i immynosypressii.– 2014. – № 4. – S. 64-68.


5. Lozano M. Implementation of pathogen reduction technologies for blood components for transfusion: updated table 2009-2010 / M. Lozano, J.-P. Cazenave, B. Braunig, M.-E. Behr-Gross // European committee (partial agreement) on blood transfusion (CD-P-TS). – Strasbourg, EDQM, 2013. – 4 p.


6. Allain J.P. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation / J.P. Allain, C. Bianco, M.A. Blajchman et al. // Trasfus. Med. Rev. – 2005 – Vol. 19, № 2. – P. 110-126.


7. Strauss-Patko M. Routine fresh frozen plasma manufacture with pathogen inactivation by methylene blue (Theraflex MB–plasma) // Vox. Sang.– 2010. – Vol. 99, Suppl. 1.– R. 253.


8. Shanmugam G. Vasoplegic syndrome – the role of methylen blue // Eur. J. Cardiothorac. Surg.– 2005. – Vol. 28, № 5. – R. 705-710.


9. Müller-Breitkreutz K., Mohr H. Hepatitis C and human immunodeficiency virus RNA degradation by methylene blue/light treatment of human plasma // J. Med. Virol.– 1998. – Vol. 56, № 3. – R. 239-245.


10. Knuever-Hopf J. Human parvovirus in plasma is highly sensitive to methylene blue/light treatment / J. Knuever-Hopf , W. Schaefer, A. Groener et al. // Vox. Sang. – 2010. – Vol. 99, Suppl. 1. – R. 240.


11. Equitoni F. MB–Photoinactivated FFP is effective and safe for treatment of coagulation and bleeding disorders / F. Equitoni, G.Mistretta, M. Hortencio de Medeiros // Vox. Sang. – 2004. – Vol. 87, Suppl. 3. – P. 72.


12. del Rio-Garma J. ADAMTS-13 activity and von Willebrand factor levels in methylene-blue photo-inactivated plasma processed by either the Springe method or an “in house” system / J. del Rio-Garma, A. Pereira, J.L. Arroyo et al. // Vox. Sang. – 2008. – Vol. 95, № 2.– R. 101-115.


13. Krol D. Usefulness of plasma subjected to pathogen reduction for cryoprecipitate production / D. Krol, B. Drybanska, J. Zyla et al. // Vox. Sang. – 2010. – Vol. 99, Suppl. 1.– R. 239.


14. Plygareva I.V., Chechetkin A.V. Ocenka kachestva virysinaktivirovannoi donorskoi plazmi // Transfyziologiya. – 2014. – № 1. – S. 57.


15. Riggert J. Filtration of methylene blue-photooxidized plasma: influence on coagulation and cellular contamination / J. Riggert, A. Humpe, T.J. Legler et al. // Transfusion. – 2001. – Vol. 41, № 1. – P. 82-86.


16. Nussbaumer W. Plasma related side effects (se) of inactivated plasma (methylene-blue treated) vs not inactivated plasma (quarantine stored) in adult and pediatric recipients / W. Nussbaumer, H. Schennach, P. Mayersbach et al. // Vox Sang. – 2014. – Vol. 107, Suppl. 1. – P. 121.


17. Prowse C. Properties of pathogen-inactivated plasma components // Transfus. Med. Rev. – 2009. – Vol. 23. – P. 124-133.


18. Pitkanen H. Enhanced thrombin generation and reduced intact protein S in processed solvent detergent plasma / H. Pitkanen, A. Jouppila, M.C. Mowinckel et al. // Thromb. Res. – 2015. – Vol. 135, № 1. – R. 167-174.


19. Bocquet T. Experience converting from methylene blue to amotosalen treated plasma // Vox Sang. – 2014. – Vol. 107, Suppl. 1. – P. 121


20. Osselaer J.C. Coagulation function in fresh-frozen plasma prepared with two photochemical treatment methods: methylene blue and amotosalen / J.C. Osselaer , C. Debry , M. Goffaux et al. // Transfusion. – 2008. – Vol. 48, № 1. – R. 108-117.


21. Lin L. Amotosalen interactions with platelet and plasma components: absence of neoantigen formation after photochemical treatment / L. Lin , M.G. Conlan , J. Tessman et al. // Transfusion. – 2005. – Vol. 45, № 10. – R. 1610-1620.


22. de Alarcon P. Fresh frozen plasma prepared with amotosalen HCl (S– 59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficiencies / P. de Alarcon, R. Benjamin, M. Dugdale et al. // Transfusion – 2005.– Vol.45, № 8. – P. 1362-1372.


23. Lehmann C. Pathogen inactivation of single donor plasma / C. Lehmann, S. Rummler, C. Kummer, D. Barz // Vox. Sang. – 2010. – Vol. 99, Suppl. 1. – R. 242.


24. Lachert E. Quality control of riboflavin and UV light treated plasma using the Mirasol PRT system / E. Lachert, J. Antoniewicz- Papis, A. Dzieciatkowska et al. // Vox. Sang. – 2010. – Vol. 99, Suppl. 1. – R. 255.


25. Bihm D.J. Characterization of plasma protein activity in riboflavin and UV light– treated fresh frozen plasma during 2 years of storage at – 30 degrees C / D.J. Bihm, A. Ettinger, K.A. Buytaert– Hoefen et al. // Vox. Sang.– 2010. – Vol. 98, № 2. – R. 108-115.


26. Maia S. Mirasol treated plasma evaluation at centro regional de sangue do Porto (instituto portugues do sangue) Porto, Portugal / S. Maia, M.L. Dobao, L. Queiros, A. et al. // Vox. Sang. – 2010. – Vol. 99, Suppl. 1. – R. 245.


27. Golovanova I.S. Razrabotka tehnologii fotoinaktivacii patogenov v gemokomponentah / I.S. Golovanova, T.D. Myraveva, S.S. Bessmelcev i dr. // Transfyziologiya. – 2014.– № 2.– S. 54-55.


28. Salado W. In vitro evaluation of platelet concentrates pathogen reduced with Theraflex UV – platelets procedure / W. Salado, C. Sumian, F. Dehaut et al. // Vox. Sang .– 2014. – Vol. 107, suppl. 1. – P. 129.


29. Quaglietta A. Post-transfusional absolute platelet increment: a comparison between standard and inactivated platelet concentrates / A. Quaglietta, M. Di Saverio, A. Pompa et al. // Vox. Sang. – 2010. – Vol. 99, Suppl. 1. – R. 255-256.


30. Pohler P. Platelet concentrates in an autologous animal model / P. Pohler, J. Lehmann, V. Veneruso et al. // Vox. Sang. – 2010.– Vol. 99, Suppl. 1. – R. 255.


31. Osselaer J.C. A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment / J.C. Osselaer, N. Messe, T. Hervig et al. // Transfusion. – 2008 Vol. 48, № 6. – R. 1061-1071.


32. Cui Z. Inactivation of lymphocytes in blood products using riboflavin photochemical treatment with visible light / Z. Cui, Y. Huang, Q. Mo, X. Wang // Photochem. Photobiol. – 2008. – Vol. 84, № 5. – R. 1195-1200.


33. Antoniewicz-Papis J. Lymphocyte survival/activation in stored platelet concentrates following gamma– irradiation or pathogen reduction technology treatment / J. Antoniewicz– Papis, J. Wozniak, A. Krzywdzinska et al. // Vox. Sang. – 2010. – Vol. 99, Suppl. 1. – R. 18.


34. Brixner V. Clinical safety and efficacy of red blood cell components treated with the S-303 pathogen inactivation system – a randomized controlled double-blind phase 3 study in patients requiring transfusion support of acute anemia / V. Brixner , A.H. Kiessling, K. Madlener et al. // Vox. Sang. – 2015. – Vol. 109, Suppl. 1. – R. 28-29.


35. Nussbaumer W. In vitro evaluation of pathogen inactivated apheresis RBC using the S-303 treatment system / W. Nussbaumer, H. Volland 1, H. Schennach et al. // Vox. Sang. – 2015. – Vol. 109, Suppl. 1. – R. 191.


36. Yonemura S. Effects of Mirasol pathogen reduction technology on red blood cell function over the course of storage as whole blood or packed red blood cells / S. Yonemura, S. Larkin, S. Doane // Vox. Sang. – 2015. – Vol. 109, Suppl. 1. – R. 188.


37. Mundt J. Whole blood storage after treatment with riboflavin and uv illumination: a pre-clinical study in Sub-Saharan Africa / J. Mundt, S. Owusu-Ofori., J. Kusi et al. // Vox. Sang. – 2014. – Vol. 107, suppl. 1. – P. 126.